BB's Stock Haven

[whatisthecolorofmone]

Nuvo Research OTC: NRIFF or Toronto Stock Exchange NRI FDA decision date is April 16, 2012.

Article of FDA decision: A sure shot

http://seekingalpha.com/article/471591-9-healthcare-stocks-with-major-catalysts-due-in-april?source=kizur

Presentation January 2012
http://www.nuvoresearch.com/investors/documents/presentations/2012-03-26%20Nuvo%20IR%20Presentation%20March_2012.pdf

Nuvo is definitely one of the most undervalued stock in the Biotech Sector . Nuvo is a unknown Gem thats the only problem with this Goldmine

Market cap of $ 36 M is really a PURE GIFT for a Biotech Company which has almost 3 FDA Products on the Market and $ 18 M in Cash

Fantastic entry point at this HUGE bargain level .Patience will payoff big time here .GLTA

Insider Activity
http://canadianinsider.com/node/7?menu_tickersearch=nri



UPCOMING MILESTONES 2012 : FDA Decision date April 16, 2012

Growing Pennsaid U.S. sales = higher royalty revenue
Covidien sNDA for Pennsaid 2%

Pliaglis approval and launch in the U.S. and E.U. = new royalty
revenue and milestone payments ( 15% royalties + $8 M milestone upon EU launch )

Relaunch Synera in the U.S. and expand in the E.U.

Announce action plan for WF10 development


Corporate Profile
Nuvo Research Inc. is a publicly traded (TSX:NRI), Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition.

The Company's Pain Group, located in West Chester, Pennsylvania, is focused on the development and commercialization of topically delivered pain products. The Company's product portfolio includes Pennsaid®, Pliaglis® and Synera®.

Pennsaid, a topical NSAID, is used to treat the signs and symptoms of OA of the knee(s). Pennsaid is sold in the United States by Mallinckrodt Inc., a Covidien company (NYSE: COV), in Canada by Paladin Labs Inc. (TSX:PLB) and in several European countries.

Pliaglis is a topical local anesthetic cream, which is FDA-approved to provide topical local analgesia for superficial dermatological procedures. The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology.

Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial dermatological procedures and in Europe, for surface anaesthesia of normal intact skin. Nuvo currently markets Synera in the United States and its licensing partner, EuroCept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan) in several European countries.

Through its subsidiary, Nuvo Research GmbH, based in Leipzig, Germany, the Company is also developing the compound WF10, for the treatment of immune related diseases